Core Viewpoint - The article discusses the potential link between paracetamol use during pregnancy and autism, highlighting the lack of substantial evidence to support this claim despite rising autism rates in the US and increased paracetamol consumption [1][2][4]. Group 1: Paracetamol Usage and Autism Correlation - Americans account for over 40% of global paracetamol consumption, spending more than $4 billion annually on acetaminophen products [1]. - Autism rates in the US have increased significantly, from approximately one in 150 children in 2000 to about one in 30 today [1]. - Some studies suggest a correlation between maternal paracetamol use during pregnancy and autism or other neurodevelopmental disorders, but these studies have not definitively proven causation [2][3]. Group 2: Confounding Factors - Factors such as parental genetics, maternal lifestyle, and the underlying reasons for paracetamol use (e.g., viral infections) may confound the observed correlation [3]. - A large study involving 2.5 million children in Sweden found only a marginal increase in autism risk associated with maternal paracetamol use, which disappeared when considering siblings born to the same mothers during pregnancies without paracetamol use [6][8]. Group 3: Health Recommendations - Health authorities, including those in the UK, continue to recommend paracetamol as the safest pain relief option during pregnancy, as other painkillers like ibuprofen may pose risks [9]. - Experts caution that avoiding paracetamol could lead to more significant health issues for both the mother and the developing baby [11][12]. Group 4: Societal Implications - The discussion around a potential link between paracetamol and autism may contribute to stigma against mothers of autistic children, which is a concern among researchers [14]. - The narrative surrounding this issue may serve as a distraction from other controversies, reflecting broader themes in US health policy [16][17].

Kenvue's stock was heading for a record low as investors express concerns over what President Trump will say regarding the use of acetaminophen — the active ingredient in Tylenol — and the autism epid... ...

Shares of Kenvue, the consumer-health spinoff of Johnson & Johnson, tumbled 7.1% to a record low of $17.03 on Monday with the selloff coming ahead of US President Donald Trump's planned announcement t... ...

Welcome back to Money Movers. Take a look at Tylenol maker Ken View. Down over 7% at record lows now following reports that the Trump administration is planning to link Tylenol to autism risk during pregnancy.A Ken View spokesperson telling CNBC in part, quote, "We believe independent sound science clearly shows that taking acetamophen does not cause autism." President Trump is scheduled to make remarks on quote significant medical and scientific findings for America's children at 400 pm Eastern time today. ...

Core Viewpoint - Ken View's stock has dropped over 7% to record lows due to reports linking Tylenol to autism risk during pregnancy, as suggested by the Trump administration [1][2] Company Analysis - Ken View's spokesperson asserts that independent science shows no causal link between acetaminophen and autism [2] - The upcoming remarks from President Trump are expected to address significant medical findings related to children's health [2] - The recent study referenced is a reanalysis of existing research from Harvard and Mount Sinai, not a new scientific study [3] - The study will also explore biological mechanisms that might explain the association between acetaminophen use and autism [4] - Concerns about potential bias exist, as two authors of the study are consultants for plaintiffs in recent litigation [4] Legal and Market Risks - The primary risk for Ken View is the potential for increased lawsuits, especially if new evidence emerges from the Trump administration's findings [5][6] - Previous litigation was dismissed due to lack of evidence, but it is currently in appeals [6] - Public opinion may pose a significant risk, potentially affecting consumer confidence and sales [7][9] Product Portfolio and Financial Impact - Tylenol is estimated to account for about 10% of Ken View's portfolio, making it a significant brand for the company [9] - There is speculation about potential asset sales, including the skin, health, and beauty segment, as well as Tylenol, to mitigate lawsuit risks [11][12] - Despite the current selloff, the stock is trading at lower levels than during previous litigation, suggesting it may be an attractive buying opportunity [14][15]

Group 1: Nvidia and OpenAI Investment - Nvidia announced a $100 billion investment in OpenAI to develop AI data centers, leading to a rise in its stock price and boosting major U.S. equity indexes [2][6] - Nvidia's investment positively impacted its partners, including Super Micro Computer and Micron Technology, which also saw their stock prices increase [2] Group 2: Semiconductor Equipment Sector - Teradyne's shares surged after Susquehanna raised its price target from $133 to $200, indicating expected growth in demand for semiconductor equipment [3] - Other semiconductor equipment manufacturers, such as Applied Materials, ASML, and Lam Research, also experienced stock price increases [3] Group 3: Apple and iPhone Demand - Apple shares rose as Wedbush increased its price target for the stock to $310 from $270, citing better-than-expected demand for the iPhone 17 [4][6] Group 4: Mergers and Acquisitions - Metsera's shares soared after Pfizer announced plans to acquire the biopharma firm for up to $7.3 billion, capitalizing on the rising demand for weight-loss medications [4] Group 5: Real Estate Sector - Anywhere Real Estate's shares increased following the announcement of its acquisition by rival Compass, while Compass's shares declined [5] Group 6: Other Notable Movements - Kenvue's shares fell after reports linking its Tylenol product to autism, while Coinbase Global's shares dropped as major cryptocurrency prices declined [5][6]

President Donald Trump is expected to give a Monday afternoon announcement linking the use of popular over-the-counter pain medication Tylenol to the development of autism during pregnancy, a claim wh... ...

Shares of Tylenol maker Kenvue (KVUE) are dropping in morning trading on a report that the White House is expected to make an announcement Monday linking pregnant women's use of the painkiller to increased risk of autism. ...

Tylenol maker Kenvue 'strongly disagrees' there is a causal link between acetaminophen use during pregnancy and autism. ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...